Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Study finds canola-type rapeseed oil decreases fibrinogen level

According to research on fatty acids conducted at the universities of Helsinki and Tampere, the consumption of canola-type rapeseed oil decreases the level of fibrinogen detrimental to health in the body. The increased fibrinogen level, caused by an imbalance in essential fats in one's diet, decreases when saturated fatty acids are replaced with rapeseed oil.

9 Nov 2010

Omthera initiates ECLIPSE study for treatment of high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.

9 Nov 2010

$Beta blockers for high blood pressure also reduce fracture risk: Study$

Beta blockers for high blood pressure also reduce fracture risk: Study

Beta blockers, one of the most commonly used types of cardiovascular drugs, taken by about 20 per cent of the population, have been found to cut a person's incidence of bone fracture by half. This new and welcome side effect was reported by Professor Tuan Nguyen from Sydney's Garvan Institute of Medical Research and his Australian-based colleagues. “Indeed, we found that men and women who used beta-blockers had a 50 per cent lower risk of fracture than those not using beta blockers… We were very excited about the finding because, as you know, a lot of elderly people use beta blockers ... it’s a very significant public health issue,” he said.

8 Nov 2010

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Ardea Biosciences, Inc. announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric®) and allopurinol.

8 Nov 2010

Crescendo Bioscience launches multi-biomarker blood test for RA

Crescendo Bioscience announced today the commercial launch of Vectra DA, its first-in-class multi-biomarker blood test designed to aid physicians in managing patients with rheumatoid arthritis (RA). Vectra DA analyzes 12 key serum biomarkers to produce a single objective score that quantifies RA disease activity.

8 Nov 2010

MedCath to sell Texsan Heart Hospital

MedCath Corporation announced today it has entered into a definitive agreement to sell substantially all the assets of Texsan Heart Hospital, owned by MedCath and its physician investors, to Methodist Healthcare System of San Antonio. The transaction is expected to close during MedCath's second fiscal quarter of 2011, which ends March 31, subject to regulatory approval and customary closing conditions.

8 Nov 2010

Apples lower risk for developing heart disease

Recent research out of the University of Michigan Health System – a premier academic medical center – has found that adding more apples and apple products to your diet may be an easy way to lower your risk for developing heart disease. More than one in three U.S. adults has one or more types of cardiovascular disease (CVD) according to the American Heart Association. Heart disease is the leading cause of death in the United States.

8 Nov 2010

Limiting inflammation can control accumulation of carotid atherosclerosis in RA patients

New data presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta show that systemic inflammation and rheumatoid arthritis disease activity may contribute to the progression of atherosclerosis in people with RA. The data also show that this progression may be modified favorably by TNF inhibitors and detrimentally by glucocorticoids.

8 Nov 2010

Helical CT scanning reduces lung cancer deaths

In a major new study announced today by the National Cancer Institute, researchers including Brown University biostatistian Constantine Gatsonis and his colleagues found that screening for lung cancer using helical CT scanning reduced lung cancer deaths by 20 percent compared to using chest X-rays.

8 Nov 2010

Skin to blood transformation in the lab

In a new study scientists have successfully transformed human skin cells into blood without first being sent through a primordial, stem-cell-like state. The findings were published online in the journal Nature. Earlier work has shown that fibroblast cells from mouse skin, treated with the right cocktail of chemicals, can be transformed into neurons and heart muscle. This is a first with human cells.

7 Nov 2010

Americans sicker but live longer than the English: Study

According to a new study in the journal Demographics, and elderly American is not quite as healthy as his English counterpart, but does live just as long, if not longer. The study found that Americans aged 55 to 64 and 70 to 80 had higher rates of chronic diseases than same-aged English people, but they died at about the same rate. Americans aged 65 and older could be sicker than their English peers but lived longer.

5 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

Scientists identify events that causes AD progression

Scientists at the Gladstone Institute of Neurological Disease (GIND) have offered new information about the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain.

4 Nov 2010

New cyber-database enables access to information on lymphedema

Lymphedema is a chronic condition that causes swelling of the limbs and affects physical, mental and social health. It commonly occurs in breast cancer survivors and is the second-most dreaded effect of treatment, after cancer recurrence. Every day, researchers throughout the world learn more about the condition and how it can be treated. Now, University of Missouri researchers are developing a place in cyberspace where relevant and timely information can be easily stored, searched, and reviewed from anywhere with the goal of improving health care through the availability of up-to-date, evidence-based research.

4 Nov 2010

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals, Inc. a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has been awarded grants totaling $977,900 under the Qualifying Therapeutic Discovery Project (QTDP) Program administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

New simple blood test may help diagnose Niemann-Pick type C disease

A fatal genetic disorder that frequently takes years to diagnose may soon be detectable with a simple blood test, researchers at Washington University School of Medicine in St. Louis and the National Institutes of Health (NIH) report this week in Simple blood test may diagnose deadly Niemann-Pick type C disease.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

MiCardia receives European CE Mark approval for enCor Mitral Valve Repair System

MiCardia Corporation announced today that it has received the CE Mark to begin marketing the Company's enCor™ Mitral Valve Repair System in the European Union.

3 Nov 2010

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010